ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Acetazolamide

Also written as “IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide”, “IHL-42X: 5 mg dronabinol + 125 mg acetazolamide” and “IHL-42X: 7.5 mg dronabinol + 125 mg acetazolamide”.

Its studies are mostly in Sleep Apnea, Obstructive · Sleep Apnea Syndromes, led by 2 companies.

Drug pageAcetazolamide: every studyAll 129 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Jun 3, 20262 company-led studies, 2 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Incannex Healthcareits history only11 open or runningphase 2since Jun 3, 2026Jun 3, 2026Apr 2027phase 2 · NCT07635563
Shionogiits history only11 open or runningphase 2since Jan 3, 2025Jan 3, 2025Dec 31, 2026phase 2 · NCT06776432

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 3, 2025First study: phase 2 study in Sleep Apnea SyndromesNew to ShionogiShionogi · NCT06776432 · 60 enrolled · United States
  2. Jun 3, 2026Incannex Healthcare’s first study: phase 2 study in Sleep Apnea, ObstructiveNew to Incannex HealthcareIncannex Healthcare · NCT07635563 · 120 planned · United States

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Sleep Apnea SyndromesShionogi · NCT06776432
  2. Apr 2027Primary completion: phase 2 study in Sleep Apnea, ObstructiveIncannex Healthcare · NCT07635563

TargetBeta

“Carbonic anhydrase I inhibitor; Carbonic anhydrase I inhibitor; Carbonic anhydrase II inhibitor; Carbonic anhydrase II inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
sulthiameruleShionogiphase 22

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07635563Sleep Apnea, Obstructive · United States2RecruitingIncannex HealthcareApr 2027120
NCT06776432Sleep Apnea Syndromes · United States2Active, not recruitingShionogiDec 31, 202660

How it is read

Names in the registry

  • “IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide”, 1 entry
  • “IHL-42X: 5 mg dronabinol + 125 mg acetazolamide”, 1 entry
  • “IHL-42X: 7.5 mg dronabinol + 125 mg acetazolamide”, 1 entry
  • “IHL-42X: 2.5 mg dronabinol + 250 mg acetazolamide”, 1 entry
  • “IHL-42X: 5 mg dronabinol + 250 mg acetazolamide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.